CBL-514 vs Retatrutide: Two Very Different Approaches in Fat-Loss Research
A localized small molecule versus a systemic triple-agonist peptide. How CBL-514 and Ret3trutide differ in mechanism, research focus and sourcing.
CBL-514 and Ret3trutide often come up together because both are studied in fat-reduction research — but they work in fundamentally different ways.
Ret3trutide: Systemic, Peptide-Based
Ret3trutide is a triple agonist (GIP, GLP-1 and glucagon receptors). It acts systemically on appetite, metabolism and energy expenditure, and is studied for overall body-weight management.
CBL-514: Localized, Small Molecule
CBL-514 is an investigational small molecule studied for localized fat reduction. Research describes it inducing lipolysis in adipocytes in a targeted area, which is why it is associated with body-contouring research rather than overall weight management.
Side-by-Side
- Type: peptide (Ret3trutide) vs small molecule (CBL-514)
- Action: systemic vs localized
- Research focus: weight management vs localized adipose reduction
- Availability at PeptideBazaar: single vials and wholesale (Ret3trutide) vs wholesale only (CBL-514, 10mg and 20mg)
Which One for Your Research?
They answer different research questions and are not interchangeable. If you need bulk CBL-514, message us on WhatsApp for rates and warehouse stock (India, US, UK).
For in-vitro research use only. Not for human or animal consumption.